Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
about
Low-density lipoprotein size and cardiovascular risk assessment.Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial.Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus.
P2860
Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Benefits of micronised Fenofib ...... ts with good glycemic control.
@ast
Benefits of micronised Fenofib ...... ts with good glycemic control.
@en
type
label
Benefits of micronised Fenofib ...... ts with good glycemic control.
@ast
Benefits of micronised Fenofib ...... ts with good glycemic control.
@en
prefLabel
Benefits of micronised Fenofib ...... ts with good glycemic control.
@ast
Benefits of micronised Fenofib ...... ts with good glycemic control.
@en
P2093
P1433
P1476
Benefits of micronised Fenofib ...... ts with good glycemic control.
@en
P2093
Shepherd J
P304
P356
10.1016/S0021-9150(00)00497-4
P577
2001-02-01T00:00:00Z